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Background: Core Binding Factor acute myeloid leukemia (CBF-AML) with t(8;21) RUNX1-MTG8 or inv(16) CBFB-MYH11
fusion proteins often show upregulation of wild type or mutated KIT receptor. However, also non-CBF-AML frequently
displays upregulated KIT expression. In the first part of this study we show that KIT expression can be also upregulated
by miR-17, a regulator of RUNX1, the gene encoding a CBF subunit. Interestingly, both CBF leukemia fusion proteins and
miR-17, which targets RUNX1-3′UTR, negatively affect a common core RUNX1-miRNA mechanism that forces myeloid cells
into an undifferentiated, KIT-induced, proliferating state. In the second part of this study we took advantage of the
conservation of the core RUNX1-miRNA mechanism in mouse and human, to mechanistically demonstrate in a mouse
myeloid cell model that increased KIT-induced proliferation is per se a mechanism sufficient to delay myeloid differentiation.
Methods: Human (U937) or mouse (32D) myeloid clonal lines were used, respectively, to test: 1) the effect of
RUNX1-MTG8 and CBFB-MYH11 fusion proteins, or upregulation of miR-17, on KIT-induced proliferation and myeloid
differentiation, and 2) the effect of upregulation of KIT-induced proliferation per se on myeloid cell differentiation.
Results: In the first part of this study we found that stable miR-17 upregulation affects, like the CBF-AML fusion
proteins (RUNX1-MTG8 or CBFB-MYH11), a core RUNX1-miRNA mechanism leading to KIT-induced proliferation of
differentiation-arrested U937 myeloid cells. In the second part of the study we harnessed the conservation of this
core mechanism in human and mouse to demonstrate that the extent of KIT upregulation in 32D mouse myeloid
cells with wild type RUNX1 can per se delay G-CSF-induced differentiation. The integrated information gathered from
the two myeloid cell models shows that RUNX1 regulates myeloid differentiation not only by direct transcriptional
regulation of coding and non-coding myeloid differentiation functions (e.g. miR-223), but also by modulating
KIT-induced proliferation via non-coding miRNAs (e.g. miR-221).
Conclusions: The novelty of this study is dual. On the one hand, miRNAs (e.g. miR-17) can mimic the effects of
CBF-AML fusion proteins by affecting a core RUNX1-miRNA mechanism of KIT-induced proliferation of undifferentiated
myeloid cells. On the other hand, the extent of KIT-induced proliferation itself can modulate myeloid differentiation of
cells with wild type RUNX1 function.
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The core binding factor (CBF), a master hematopoietic
transcription factor that controls the transcription of
genes involved in both embryonic and post-embryonic
hematopoietic development, is composed of two subunits:
the CBFA2 subunit, encoded by the RUNX1 (AML1) gene* Correspondence: nicoletta.sacchi@roswellpark.org
†Equal contributors
1Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo NY
14263, USA
Full list of author information is available at the end of the article
© 2015 Fischer et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.on chromosome 21, and the CBFB subunit, encoded by
the CBFB gene on chromosome 16. While RUNX1 binds
DNA at specific consensus sequences in the regulatory
regions of target genes, CBFB strengthens RUNX1
DNA-binding [1-4]. Both RUNX1 and CBFB undergo
chromosomal rearrangements in acute myeloid leukemia
(AML). The two most common AML chromosome re-
arrangements, the t(8;21) (q22; q22) and the inv(16) (p13;
q22), generate the RUNX1-MTG8 (AML1-ETO) and
CBFB-MYH11 fusion proteins, respectively. According toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fischer et al. Molecular Cancer  (2015) 14:7 Page 2 of 13the French-American-British (FAB) classification, t(8;21)-
positive leukemia is mostly M2, while inv(16)-positive
leukemia is mostly M4Eo [3,5-7].
RUNX1-MTG8 not only affects RUNX1 allelic dosage,
but also exerts a dominant negative action on RUNX1
target genes [1,5]. CBFB-MYH11, by binding RUNX1,
also exerts a dominant negative action on RUNX1 target
genes and, by sequestering RUNX1 into the cytoplasm,
depletes RUNX1 in the nucleus [5,8,9]. Thus, even if in
a different manner, both CBF-AML fusion proteins affect
RUNX1 dosage as well as RUNX1 transcriptional regula-
tory function of both coding and non-coding RUNX1-
target genes implicated in hematopoiesis [5,8,10,11].
The first described non-coding RUNX1-target was miR-
223, which is critical for the establishment of both gran-
ulocyte and monocyte lineages [12-15]. RUNX1-MTG8
binding to RUNX1 consensus sequences in the miR-223
promoter region induces miR-223 transcriptional re-
pression and block of myeloid differentiation in t(8;21)
leukemia cells [12]. Subsequently, we found that the
miR-222/221 gene cluster, involved in the regulation of
the KIT receptor by targeting KIT-3'UTR [16], is also a
direct RUNX1-target, whose transcription is repressed
by the dominant negative t(8;21) RUNX1-MTG8 fusion
protein [17].
We also reported that both t(8;21) and inv(16) CBF-
AML display lower levels of miR-221 and miR-222 relative
to non-CBF-AML, in association with increased expres-
sion of the KIT receptor (CD117 antigen) [17]. In this
study we mechanistically demonstrate that, like RUNX1-
MTG8, also CBFB-MYH11 interferes with RUNX1-CBFB.
Thus, both CBF-AML fusion proteins negatively affect
both the RUNX1-miR-221-KIT axis and RUNX1-miR-
223 transcription, leading to increased KIT-induced
proliferation of undifferentiated myeloid cells.
Interestingly, a significant number of non-CBF-AMLs
also display elevated levels of KIT relative to non-leukemic
cells [18-21]. Intrigued by this observation, we tested
whether other factors, capable of interfering with RUNX1-
CBFB regulatory function, can also negatively affect the
RUNX1-miR-221-KIT axis and miR-223 transcription. In
this study we focused on miR-17, a miRNA that, by target-
ing RUNX1-3′UTR, plays a key role in the control of
RUNX1 expression and myeloid differentiation [22]. We
found that the effects of ectopic miR-17 expression mimic
the biological effects induced by the RUNX1-MTG8 and
CBFB-MYH11 fusion proteins by affecting the same core
mechanism: the RUNX1-miR-221-KIT axis and miR-223.
In the second part of this study we took advantage of
the core mechanism conservation between human and
mouse so that we could use the 32D mouse myeloid cell
model to monitor cytokine-induced myeloid differenti-
ation over a period of 12 days. In the 32D model, with a
functional wild type RUNX1, we could demonstrate thatin the absence of any factor that negatively interferes
with RUNX1, the extent of KIT-induced proliferation
per se determines a delay of cytokine-induced myeloid
differentiation. Thus, KIT-induced proliferation is a mech-
anism that normally determines the timing of RUNX1-
mediated myeloid differentiation processes.
Results
Both t(8;21) and inv(16) leukemia fusion proteins affect
the same RUNX1-miRNA-KIT axis regulating KIT proliferation
activity
Previously, we reported that in t(8;21) and inv(16) CBF-
AML samples there is upregulation of KIT (CD117 anti-
gen) concomitant with downregulation of miR-221, a
RUNX1-regulated miRNA that targets KIT-3'UTR [17].
Studies from other laboratories showed that the RUNX1-
MTG8 fusion protein, derived from the t(8;21) cytogenetic
rearrangement, decreases RUNX1 dosage and exerts a
dominant negative action over wild type RUNX1 (see
scheme in Figure 1A, left, based on [1,5]). The CBFB-
MYH11 fusion protein derived from the inv(16) re-
arrangement would interfere with the wild type RUNX1
function both by depleting the nucleus of RUNX1 through
sequestration into the cytoplasm and by exerting a domin-
ant negative action over wild type RUNX1 (Figure 1A,
right, based on [8,9]).
Transient transfection of human U937 myeloid cells with
a luciferase reporter driven by the miR-221 promoter
shows that RUNX1, alone or in combination with CBFB,
induces miR-221 transcription, while both RUNX1-MTG8
and CBFB-MYH11 repress miR-221 promoter (Figure 1B).
Stable ectopic expression of either RUNX1-MTG8 or
CBFB-MYH11 in the U937 cell context increases the
proportion of KIT (CD117)-positive cells (Figure 1C)
and promotes cell proliferation (Figure 1D), relative to
control U937EV cells carrying the cognate empty vector.
Thus, the two CBF-AML fusion proteins, by interfering
with wild type RUNX1 transcriptional function, induce
miR-221 downregulation concomitant with KIT-induced
proliferation.
Stable expression of miR-17 deregulates the same core
RUNX1-miR-221-KIT axis affected by CBF-AML fusion
proteins
KIT upregulation was reported in 60-80% of all AML, in-
cluding CBF-AML and non-CBF-AML [18-21]. Because
CBF-AML represents only 15-20% of AML [3,23], we
searched for other factors that could explain KIT upregu-
lation in non-CBF-AML. According to in silico analysis
(TargetScan), the RUNX1-3′UTR contains 22 conserved
miRNA binding sites, which are predicted to be targeted
by 60 different miRNAs (Additional file 1: Figure S1A,
based on Additional file 2: Table S1). Among these, we
focused on miR-17-5p (hereafter simply referred to as
Figure 1 Both t(8;21) and inv(16) leukemia fusion proteins affect the same RUNX1-miRNA-KIT axis regulating KIT proliferation activity.
(A) Scheme based on literature showing the mechanisms that affect RUNX1 function in t(8;21) and inv(16) CBF-AML [1,5,8,9]. (B) A luciferase
reporter driven by the miR-221 promoter is activated by RUNX1, alone or in combination with CBFB, while it is repressed by RUNX1-MTG8 or
CBFB-MYH11 in transiently transfected U937 cells. (C-D) U937 clones stably expressing either RUNX1-MTG8 (U937RUNX1-MTG8) or CBFB-MYH11
(U937CBFB-MYH11) display a significant increase (p < 0.05) of KIT-positive cells (assessed by CD117 cytofluorimetric analysis in panel C) as well as
increased cell proliferation (assessed by EdU incorporation assay in panel D). Shown here one representative clone out of 3 clones stably expressing
RUNX1-MTG8 or CBFB-MYH11.
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key role in RUNX1-mediated control of myeloid differen-
tiation [22], and is often upregulated in leukemia [24].
By examining published miRNA expression datasets
from AML patients [24,25], we observed that miR-17 is
upregulated in approximately 60% of non-CBF-AML cases,
while it is mostly downregulated in CBF-AML cases
(Additional file 1: Figure S1B, top). Interestingly, miR-17
upregulation is mostly associated with the FAB M5
subtype (Additional file 1: Figure S1B, bottom), which
is frequently characterized by KIT upregulation [18].Consistent with these observations, we found evidence
of concomitant KIT (CD117) and miR-17 upregulation
in three out of 10 non-CBF-AML patient samples ana-
lyzed in our laboratories (Additional file 1: Figure S1C).
Based on these preliminary observations, we set out to
assess the effects of stable ectopic miR-17 expression in
U937 cells on both miR-221 and KIT expression. To this
end, we stably transfected U937 cells with a plasmid
co-expressing a GFP tracking insert adjacent to either
the miR-17 precursor or a scrambled control sequence
(Figure 2A, left). Next, we selected stable U937miR-17 and
Figure 2 Stable expression of miR-17 deregulates the same core RUNX1-miR221-KIT axis affected by CBF-AML fusion proteins. (A) Stable
U937 clones ectopically expressing miR-17 (U937miR-17) or a control scrambled sequence (U937Scram) were developed by transfection with a construct
co-expressing GFP and the miRNA precursor of interest (left). Cytofluorimetric analysis shows GFP expression in representative U937miR-17 and U937Scram
clones (right). (B) Stable ectopic expression of miR-17 leads to RUNX1 downregulation, as shown by decreased luciferase activity (bottom) in a
representative U937miR-17 clone transfected with a reporter plasmid carrying luciferase upstream of RUNX1-3′UTR (top). (C) Ectopic expression
of miR-17 increases both the number of KIT-positive cells (p < 0.05) (left) and cell proliferation (right). (D) Like RUNX1-MTG8 and CBFB-MYH11,
miR-17 downregulates miR-221 expression (left). Consistently, both CBF-AML and non-CBF-AML display miR-221 downregulation (right). (E) U937 cells
transiently transfected with a synthetic anti-miR inhibiting endogenous miR-221 activity display a significant (p <0.01) increase of KIT-positive cells (left)
and increased proliferation (right) relative to U937 transiently transfected with a control anti-miR scrambled sequence. (F) Stable ectopic expression of
wild type KIT in U937 cells (U937KIT) (left) is sufficient to promote proliferation (right). (G) These results indicate that miR-17, by affecting the
RUNX1-miR-221 mechanism, leads to KIT upregulation. Shown here one representative clone out of 3 clones stably expressing RUNX1-MTG8,
CBFB-MYH11, or miR-17.
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right) and transfected them with a Luc-RUNX1-3′UTR
reporter carrying the luciferase sequence upstream of
RUNX1-3′UTR (Figure 2B, top). Clones with decreased
luciferase expression (a prototypic clone out of three is
shown in Figure 2B, bottom) were bona fide miR-17-
positive clones. U937miR-17 clones showed a higher pro-
portion of KIT (CD117)-positive cells (Figure 2C, left)
as well as increased EdU-proliferation (Figure 2C, right)
relative to control U937Scram clones.
Apparently, in the U937 cell context miR-17 ectopic
expression significantly reduced miR-221 level, thus recap-
itulating the effect of RUNX1-MTG8 and CBFB-MYH11
(Figure 2D, left). This finding is in agreement with miR-
221 downregulation not only in CBF-AML, but also in
50-60% of non-CBF-AML (Figure 2D, right, based on our
previous report [17]). Transient transfection of wild type
U937 with a synthetic anti-miR-221 targeting endogen-
ous miR-221 induced a significant increase of KIT-positive
cells (Figure 2E, left) as well as increased EdU-proliferation
(Figure 2E, right). Stable ectopic expression of wild
type KIT in the U937 context (U937KIT) at a level compar-
able (5-10%) to the one detected in U937miR-17,
U937RUNX1-MTG8, and U937CBFB-MYH11 clones (Figure 2F,
left) was per se sufficient to increase EdU-proliferation
(Figure 2F, right).Figure 3 Stable expression of miR-17 downregulates RUNX1-regulated miR
(A), RUNX1-MTG8, or CBFB-MYH11 (B) display block of PMA-induced myeloid diffe
cognate control clones. (C) Consistently, U937miR-17, U937RUNX1-MTG8, and U937CBFB-Altogether, these findings show that ectopic miR-17 ex-
pression deregulates the same RUNX1-miR-221-KIT axis,
which is also deregulated by CBF-AML fusion proteins
(Figure 2G). Of note, both miR-17 and CBF-AML fusion
proteins can affect other RUNX1-regulated miRNAs tar-
geting KIT-3′UTR (see TargetScan analysis in Additional
file 3: Table S2). For instance, as shown in Additional
file 1: Figure S2, left, miR-193a is significantly downregulated
in U937miR-17, U937RUNX1-MTG8, and U937CBFB-MYH11 clones.
Stable expression of miR-17 downregulates RUNX1-
regulated miRNAs of myeloid differentiation
Treatment with the phorbol ester PMA is a common
method to induce U937 cells to rapidly (48-72 h) differ-
entiate into monocytes expressing specific surface mye-
loid antigens, such as CD11b (Figure 3A and Figure 3B,
left). U937miR-17 clones (Figure 3A, right), similar to
U937RUNX1-MTG8 and U937CBFB-MYH11 clones (Figure 3B,
middle and right), displayed a decrease of CD11b-
positive cells in response to PMA, thus indicating mye-
loid differentiation arrest. Consistently, the U937miR-17,
U937RUNX1-MTG8 and U937CBFB-MYH11 clones also dis-
played significant downregulation of RUNX1-regulated
miRNAs involved in myeloid differentiation, such as
miR-223 (Figure 3C) and miR-27a (Additional file 1:
Figure S2, right) [13,26].NAs of myeloid differentiation. (A-B) U937 clones stably expressing miR-17
rentiation (assessed by CD11b cytofluorimetric analysis) relative to their
MYH11 clones also display downregulation of miR-223 (assessed by qRT-PCR).
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matically summarized in Figure 4) let us conclude that
miR-17 deregulates a core RUNX1-miRNA mechanism of
CBF-AML pathogenesis, since it recapitulates the same ef-
fects of both RUNX1-MTG8 and CBFB-MYH11 fusion
proteins. Notably, miR-17 is only one of many miRNAs
targeting RUNX1-3′UTR (Additional file 2: Table S1).
Some of these miRNAs (e.g. miR-18a, miR-20a, miR-93)
are upregulated in a high proportion of non-CBF-AML,
and are associated with distinct AML subtypes (Additional
file 1: Figure S3). This makes us speculate that these
miRNAs, alone or in combination, could also regulate the
core RUNX1-miRNA mechanism that governs prolifera-
tion and myeloid differentiation.
Evidence that the RUNX1-miRNA core mechanism is
conserved between human and mouse
Previously we reported that the RUNX1 consensus se-
quences of the miR-221 and miR-223 promoters, as well
as the miR-221 and miR-223 seed sequences, are conserved
between human and mouse [17]. Consistently, in mouse
myeloid 32D cells, stable expression of RUNX1-MTG8
also leads to downregulation of miR-221 and miR-223
(Figure 5A). Concomitantly, 32DRUNX1-MTG8 cells also
display an increased proportion of KIT-positive cells
(Figure 5B), and are no longer able to undergo myeloid
differentiation in response to granulocyte colony stimu-
lating factor (G-CSF). Indeed, in the presence of G-CSF
(10 ng/ml), 32DRUNX1-MTG8 cells do not acquire changes
typical of granulocytes, such as increased CD11b expres-
sion (Figure 5C, left) and nuclear segmentationFigure 4 MiR-17 deregulates a core RUNX1-miRNA mechanism of CBF-A
and CBFB-MYH11 fusion proteins interfere with the same core RUNX1-miRNA
differentiation. MiR-17 and the two fusion proteins are expected to prod
different leukemia FAB subtypes. Other miRNAs targeting RUNX1-3′UTR(Figure 5C, middle). Moreover, in contrast to control
32DEV cells, 32DRUNX1-MTG8 cells continue to proliferate
even after day 7 (Figure 5C, right).
These findings let us hypothesize that the RUNX1-
miRNA-KIT mechanism of proliferation can have an in-
fluence on the myeloid differentiation process. Thus, in
the second part of this study, we took advantage of the
32D cell model to test whether KIT-mediated prolifera-
tion can per se affect myeloid differentiation.
The extent of KIT expression per se delays myeloid
differentiation in cells with functional RUNX1
To mechanistically assess whether increasing KIT ex-
pression per se can affect G-CSF-induced differentiation,
we developed 32D clones expressing exogenous mouse
wild type KIT (assessed as CD117 antigen) at low (5-10%)
or high (>80%) level relative to control 32DEV cells
(Figure 6A). Specifically, we used a 32DKIT-Low clone ex-
pressing KIT at a level comparable to the 32DRUNX1-MTG8
clone (shown in Figure 5B), and a 32DKIT-High clone ex-
pressing KIT at a level comparable to a t(8;21)-positive
leukemia cell line, the Kasumi cell line (data not shown).
32DEV, 32DKIT-Low, and 32DKIT-High cells treated with
increasing concentrations of G-CSF (0.4, 2, and 10 ng/ml)
were analyzed for both cell proliferation and induction of
CD11b myeloid antigen over a 12 day period. Control 32DEV
cells proliferated exponentially up to day 7 before plateauing
and dying (Figure 6B, gray line). Concomitantly, CD11b
expression increased in a time-dependent and G-CSF dose-
dependent manner. By day 9, almost all 32DEV cells reached
full differentiation (Figure 6C and 6D, gray bars). UponML pathogenesis. Scheme showing that miR-17 and the RUNX1-MTG8
mechanism that regulates KIT-mediated proliferation and myeloid
uce distinct phenotypes, which may explain their association with
could also affect the RUNX1-miRNA core mechanism.
Figure 5 Evidence that the RUNX1-miRNA core mechanism is conserved between human and mouse. (A) Stable ectopic expression of
RUNX1-MTG8 in 32D myeloid cells (here shown a representative 32DRUNX1-MTG8 clone) leads to downregulation of both miR-221 and miR-223 relative
to a 32DEV control clone. (B) Consistently, CD117 cytofluorimetric analysis shows a significantly (p < 0.05) higher number of KIT-positive cells in
32DRUNX1-MTG8 relative to 32DEV. (C) 32DRUNX1-MTG8 display block of granulocytic differentiation in response to G-CSF, as shown by both CD11b
cytofluorimetric analysis (left) and Giemsa staining of cytospin preparations (middle), as well as increased proliferation (right) relative to 32DEV.
Shown here one representative clone for each construct.
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cells displayed significantly increased proliferation relative to
control 32DEV cells, particularly at the lower G-CSF concen-
trations (Figure 6B and Additional file 4: Table S3).
When we analyzed CD11b expression at key time points
of G-CSF-induced differentiation (5, 7, and 9 days),
the most significant differences were detected between
32DKIT-High and 32DEV clones. First, by taking into con-
sideration individual G-CSF concentrations (Figure 6C
and Additional file 4: Table S3), it was apparent that
32DKIT-High cells failed to differentiate at the lowest
(0.4 ng/ml) G-CSF concentration across all time points
(p = 6.7−7), while they were able to differentiate to a level
similar to the 32DEV clone by day 9 at the highest (10 ng/
ml) G-CSF concentration (p = 0.91). Second, by taking into
consideration individual time points (Figure 6D and
Additional file 4: Table S3), it was apparent that the
32DKIT-High cells had significantly lower CD11b on day 5
(p = 6−5) and day 7 (p = 0.02) across all G-CSF concentra-
tions, but they reached a level of differentiation similar to the32DEV clone (p = 0.12) on day 9, at the higher G-CSF con-
centrations. Finally, when we took into consideration the
level of exogenous KIT expression, 32DKIT-Low cells displayed
a G-CSF differentiation response which was intermediate
between 32DEV and 32DKIT-High cells (Figure 6C and 6D).
These findings indicate that the extent of KIT-induced
proliferation per se plays a critical role in delaying
G-CSF-induced myeloid differentiation.
Inhibition of KIT activity counteracts the delay effect on
myeloid differentiation due to KIT overexpression
We assessed whether inhibition of KIT proliferation ac-
tivity could counteract G-CSF-induced myeloid differen-
tiation by treating 32DKIT-High cells with imatinib (1 μM),
a receptor tyrosine kinase inhibitor targeting KIT [27].
Imatinib significantly reduced the proliferation of
32DKIT-High cells relative to cells grown only in the pres-
ence of G-CSF (10 ng/ml), but did not significantly affect
the proliferation of 32DEV control cells (Figure 7A and
Additional file 4: Table S3). This indicates that the anti-
Figure 6 The extent of KIT expression per se delays myeloid differentiation in cells with functional RUNX1. (A) CD117 cytofluorimetric
analysis showing ectopic KIT expression in 32DKIT-Low and 32DKIT-High stable clones. (B) Growth curves showing increased proliferation of 32DKIT-Low and
32DKIT-High clones relative to the 32DEV control clone in response to different concentrations of G-CSF. (C-D) CD11b cytofluorimetric analysis
shows that increasing KIT expression delays G-CSF-induced differentiation in a G-CSF dose-dependent (C) and time-dependent manner (D). See text
and Additional file 4: Table S3 for statistical significance.
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Figure 7 Inhibition of KIT activity counteracts the delay effect on myeloid differentiation due to KIT overexpression. (A) Imatinib (1 μM)
significantly decreases the proliferation of 32DKIT-High cells during G-CSF-induced differentiation, while it does not affect control 32DEV cells. (B) CD11b
cytofluorimetric analysis at different time points during G-CSF-induced differentiation showing that the KIT-induced delay of myeloid differentiation in
32DKIT-High cells is counteracted by imatinib. See Additional file 4: Table S3 for statistical significance.
Fischer et al. Molecular Cancer  (2015) 14:7 Page 9 of 13proliferative effect of imatinib was likely due to specific
inhibition of KIT activity. By measuring CD11b at various
time points (day 5, 7, and 9) during G-CSF treatment, we
found that imatinib did not significantly change CD11b
level in 32DEV control cells, but increased the CD11b
level of the 32DKIT-High cells to the level detected in the
32DEV cells by day 7 (Figure 7B). Thus, imatinib was able to
counteract the KIT-induced delay of myeloid differentiation.
Based on the overall findings in the 32D mouse model,
we conclude that the proliferation effect of increased
KIT can per se delay myeloid differentiation. In the pres-
ence of factors that impair RUNX1 function/level, this
delaying effect likely reinforces the effects of direct deregu-
lation of RUNX1-regulated target genes (e.g. miR-223)
involved in myeloid differentiation (Figure 8).Figure 8 RUNX1 regulates myeloid differentiation by modulating the
RUNX1-miRNA mechanism, cells respond to myeloid differentiation stimuli,
absence of factors interfering with RUNX1, is sufficient to delay myeloid dif
miRNA mechanism (e.g. CBF fusion proteins or miRNAs targeting RUNX1-3′
deregulation of miRNAs controlled by RUNX1 and involved in differentiatio
differentiation (right).Discussion
In the first part of this study, we show that ectopic expres-
sion of miR-17, which controls RUNX1 level by targeting
RUNX1-3′UTR [22], in human U937 cells leads to deregula-
tion of a core RUNX1-regulated miRNA mechanism that is
similarly affected by the t(8;21) RUNX1-MTG8 and inv(16)
CBFB-MYH11 fusion proteins. Apparently, KIT receptor up-
regulation in CBF-AML and non-CBF-AML can be induced
not only by genetic factors (CBF-AML fusion proteins), but
also epigenetic factors (miRNAs targeting RUNX1-3′UTR)
that interfere with wild type RUNX1 function.
Notably, acute myeloid leukemia with t(8;21), inv(16), or
upregulation of miR-17 fall into FAB subtypes with
distinct phenotypic features. It is plausible that these
phenotypic differences are due to distinct mechanisms ofextent of KIT-induced proliferation. In the presence of a functional
such as G-CSF (left). Increasing KIT-mediated proliferation, even in the
ferentiation (middle). In the presence of factors that impair the RUNX1-
UTR), the effect of KIT-mediated proliferation reinforces the effects of
n (e.g. miR-223), thus resulting in complete block of myeloid
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stance, RUNX1-MTG8 and CBFB-MYH11, which are
mostly associated with the M2 and M4Eo FAB subtypes,
respectively, exert dominant negative effects over wild type
RUNX1 through different mechanisms [1,5,8,9]. Moreover,
RUNX1-MTG8 (but not CBFB-MYH11) can bind other
MTG proteins [28]. In the case of miR-17 overexpression,
which is mainly associated with the M5 FAB subtype, the
phenotype could be due to deregulation of other miR-17
targets, besides RUNX1.
In addition to CBF-AML fusion proteins and miR-17,
other factors could deregulate RUNX1 function or level.
For instance, in silico analysis of published miRNA expres-
sion datasets allowed us to highlight several miRNAs that
could potentially target RUNX1-3′UTR and that, like
miR-17, are upregulated in non-CBF-AML. Further, de-
regulation of canonical RUNX1 transcriptional regula-
tors (e.g. GATA-2 and regulatory Ets proteins) and even
long non-coding RNAs affecting RUNX1 chromatin state,
such as the recently discovered RUNXOR [29], may ultim-
ately affect the core RUNX1-miRNA mechanism that
regulates myeloid cell proliferation and differentiation.
Proliferation and differentiation are intimately linked
processes, and deregulation of one can impact the other
[30,31]. In the second part of this study, by taking advan-
tage of the conservation of the core RUNX1-miRNA-KIT
axis between human and mouse myeloid cells, we found
evidence that KIT-induced proliferation can per se influ-
ence G-CSF-induced granulocytic differentiation of 32D
myeloid cells. Specifically, increasing KIT level negatively
affects 32D myeloid differentiation both in a time- and
G-CSF dose-dependent manner. Therefore, the extent
of KIT pro-proliferative signaling can oppose differenti-
ation signalings, such as the G-CSF signaling. Indeed,
modulation of KIT-mediated proliferation with imatinib,
an inhibitor of KIT receptor activity, favors G-CSF-
induced 32D differentiation. In contrast, stable expres-
sion of RUNX1-MTG8, which irreversibly affects the
RUNX1-miRNA-KIT mechanism, promotes the prolifera-
tion of myeloid cells that are unresponsive to G-CSF. In
the latter case, the delay of GCSF-induced differentiation
due to KIT proliferation is reinforced by the repression of
RUNX1-regulated coding and non-coding (e.g. miR-223)
differentiation functions (Figure 8).
Conclusions
In conclusion, on the one hand, miRNA-mediated deregu-
lation of RUNX1 function mimics the effects of CBF-
AML fusion proteins by affecting a core RUNX1-miRNA
mechanism of KIT-induced proliferation of undifferenti-
ated myeloid cells. On the other hand, the extent of
KIT-induced proliferation itself can modulate the process
of differentiation of myeloid cells with normal RUNX1
function.Methods
AML patient samples
Patient samples were obtained in compliance with the
Helsinki declaration as per Institutional Review Board
guidelines of the Niguarda Hospital, Milan, Italy. Leukemic
mononuclear cells (MNCs), isolated from the bone marrow
of 10 patients with de novo non-CBF-AML according to
the French-British-American (FAB) classification, did not
show cytogenetic evidence of CBF rearrangements.
Samples were analyzed for KIT (CD117) expression by
flow cytometry and for miR-17 expression by qRT-PCR.
DNA sequencing of RUNX1 exons excluded the presence
of mutations in those samples showing upregulation of
both KIT and miR-17.
In silico analyses
The 3′UTRs of human RUNX1 mRNA (NM_001001890)
and human KIT mRNA (NM_001093772) were analyzed
by using TargetScan Version 6.2: June 2012 (http://www.
targetscan.org). The predicted miRNA-targeting sites con-
served among vertebrates were chosen to generate a
list of putative miRNAs targeting the RUNX1-3′UTR
(Additional file 2: Table S1) or KIT-3′UTR (Additional
file 3: Table S2). The expression of miR-221 in AML
patient samples (12 non-CBF-AML and 27 CBF-AML)
was evaluated from our previous miRNA expression
data [17]. The expression of miR-17, miR-18a, miR-20a,
miR-93, and miR-181 in AML patient samples was evalu-
ated from published gene expression datasets [24,25].
Specifically, 52 non-CBF-AML and 31 CBF-AML were
analyzed for miR-17, 31 non-CBF-AML and 18 CBF-AML
were analyzed for miR-18a, 53 non-CBF-AML and 34
CBF-AML were analyzed for miR-20a, 34 non-CBF-AML
and 18 CBF-AML were analyzed for miR-93 and miR-181.
The miRNAs were classified as upregulated, down-
regulated, or unchanged relative to the centered mean
and plotted by AML subtype.
Plasmid cloning
Human RUNX1-MTG8 cDNA was PCR-amplified from
pcDNA3.1-RUNX1-MTG8 [28], with primers introducing
Xho I and Not I restriction sites (forward: 5′ – AGA TCT
CGA GAT GCG TAT CCC CGT AGATGC – 3′; reverse:
5′ – GAC AAG CGG CCG CCT AGC GAG GGG TTG
TCT CTA – 3′), and inserted into compatible restriction
sites of the pLNCX2 plasmid. Human CBFB-MYH11
cDNA was subcloned from the pGEM-CMVa-CBFB-
MYH11 plasmid (kindly provided by Dr. Paul Liu, NIH,
Bethesda, MD) by restriction digestion using Hind III and
Not I restriction enzymes (New England BioLabs, Ipswich,
MA) and inserted into compatible restriction sites of
pLNCX2. The mouse KIT cDNA was subcloned from
pCMV-Sport6-c-Kit (GE Dharmacon, Lafayette, CO)
into compatible restriction sites of pLNCX2. The
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(Dana-Farber/Harvard Cancer Center DNA Resource
Core) with primers introducing Xho I and Not I restric-
tion sites (forward: 5′ - AGA TCT CGA GAC CAT
GAG AGG CGC TCG CGG CGC CT – 3′; reverse: 5′ –
ACC TGC GGC CGC TCA GAC ATC GTC GTG CAC
AAG C – 3′) and inserted into compatible restriction sites
of pLNCX2. All plasmids were sequenced to confirm
the absence of mutations.
Stable cell clones and culture conditions
Human leukemic monocyte lymphoma U937 cells and
derived clones were cultured in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum (Life
Technologies, Carlsbad, CA). Mouse myeloid 32D/WT1
cells, ectopically expressing human granulocyte colony-
stimulating factor receptor (G-CSFR) [32], and derived
clones were cultured in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum (Life
Technologies) supplemented with 10 ng/ml of mouse IL-3
(PeproTech, Rocky Hill, NJ). All cultures were maintained
at a concentration between 0.2 × 106-1.0 × 106 cells/ml.
U937 and 32D stable clones were obtained by stable
transfection with pLNCX2-RUNX1-MTG8, pLNCX2-
CBFB-MYH11, or pLNCX2-KIT using Lipofectamine LTX
with Plus reagent (Life Technologies), according to the
manufacturer’s instructions. In parallel, cells were also
transfected with the cognate pLNCX2 empty vector to
obtain control clones. After 48 hours of transfection,
cells were seeded in limiting dilutions in 96-well plates
and selected with 1 mg/ml of G418. Single clones were
expanded and screened for the presence of the trans-
fected construct by PCR. Expression and function of
RUNX1-MTG8 or CBFB-MYH11 in positive clones was
confirmed by RT-PCR with specific primers [33], and
the effect on transcription of known RUNX1-target
genes (e.g. MPO, CSF1R). Expression of exogenous KIT
was assessed by cytofluorimetric analysis as described
below.
To develop U937 clones stably expressing ectopic miR-
17 or cognate control clones, cells were transfected with
pEZX-MR04 plasmid (GeneCopoeia, Rockville, MD)
containing either the miR-17 precursor or a scrambled
sequence, respectively. Single clones were selected with
1 μg/ml of puromycin and screened for expression of
GFP, which is constitutively expressed from the pEZX-
MR04, by cytofluorimetric analysis. GFP-positive clones
showing significant downregulation of luciferase-RUNX1-
3′UTR were selected for further analysis. Only prototypic
clones are shown in the figures of this manuscript.
Flow cytometry analysis
AML patient samples were analyzed for KIT (CD117)
expression as previously described [17]. For cytofluorimetricanalysis of U937 and 32D clones, 1 × 106 cells were resus-
pended in blocking buffer (PBS + 0.5% BSA) in a total vol-
ume of 100 μl. After adding fluorescently labeled antibodies
against human KIT (BV-CD117, BD Biosciences, San Jose,
CA), mouse KIT (PE-CD117, Miltenyi Biotec, San Diego,
CA), or mouse/human CD11b (FITC-CD11b or PE-
CD11b, Miltenyi Biotec), cells were incubated for 20 mi-
nutes at 4°C in the dark. Unstained cells were used as a
negative control. After incubation, cells were washed,
resuspended in 500 μl of blocking buffer and analyzed by
flow cytometry on a LSR Fortessa cytometer (BD Bio-
sciences). Data were analyzed using WinList software.
Statistical significance was calculated by using the
Student’s t-test.
EdU cell proliferation assay
Cell proliferation was assessed by EdU incorporation,
using the Click-iT EdU imaging kit (Life Technologies)
as per manufacturer’s instructions. Briefly, 0.2 × 106 cells/ml
were seeded in fresh growth medium, let grow for 48 h,
incubated with 10 μM EdU for 20 minutes, and trans-
ferred to glass microscope slides using a cytospin. The
slides were fixed and permeabilized with 100% Methanol,
incubated for 30 minutes in PBS containing 3% BSA,
reacted with the Click-iT reaction cocktail (containing
azide-conjugated Alexa Fluor 594) for 30 minutes,
counterstained with DAPI, and mounted with Vectashield
(Vector Laboratories, Burlingame, CA). Slides were
examined by fluorescence microscopy to count the
EdU-positive and DAPI-positive nuclei of at least 10
random fields. Proliferation was evaluated by calculat-
ing the ratio between EdU-positive and DAPI-positive
cells. Statistical significance was calculated by using the
Student’s t-test.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated from cells with the single-step
method [34] using Trizol (Life Technologies). 50 ng of
total RNA was retrotranscribed into cDNA by using the
TaqManW miRNA Reverse Transcription kit and TaqManW
assay RT primers specific for each of the miRNA of
interest, according to the manufacturer’s instructions
(Life Technologies). A TaqManW assay RT primer for
RNU-44, a human small nucleolar RNA, was used as an
internal loading control for human cells, and a TaqManW
assay RT primer for sno-202, a mouse small nucleolar
RNA, was used as an internal loading control for mouse
cells. The levels of miRNA cDNAs were quantitated by
real-time PCR analysis using specific TaqManW assay
real-time primers (Life Technologies) for each miRNA
of interest, as well as for the small nucleolar RNA in-
ternal loading controls. Real-time PCR was performed
on an iCycler (BioRad, Hercules, CA) using the iQ
Supermix (BioRad) and quantitated from triplicate
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significance was calculated by the Student’s t-test.
Luciferase reporter assays
For miR-221-promoter luciferase assay, U937 cells grown
in a 24-well plate were transfected by using Lipofectamine
LTX (Life Technologies) with 10 ng of pRL-TK (Promega,
Madison, WI), 300 ng of (-1600) MIR-222/221-Luc (kindly
provided by Carlo Croce, Ohio State University), in
combination with 300 ng of either pCMV5-RUNX1B
(Addgene, Cambridge, MA), pcDNA3.1-AML1-MTG8-V5
[28], pGEM-CMV-CBFB, or pGEM-CMV-CBFB-MYH11
(both kindly provided by Paul Liu, NIH, Bethesda, MD).
For RUNX1-3′UTR luciferase assay, cells seeded into 24-
well plates were co-transfected with 10 ng of the pRL-TK
and either 500 ng of pGL4.13-RUNX1-3′UTR plasmid,
containing the RUNX1-3′UTR downstream of the firefly
luciferase coding sequence (kindly provided by Yoram
Groner, Weizmann Institute, Israel), or 500 ng of the con-
trol pGL4.13 plasmid. The concentration of transfected
DNA was kept constant by adding an appropriate amount
of empty pcDNA3.1. After 24 hours, cells were lysed in
passive lysis buffer and measured for luciferase activity
using the Dual Glow Luciferase Assay System (Promega)
and a Veritas Luminometer (Tuner Biosystems, Sunnyvale,
CA) as per manufacturer′s instructions. Statistical signifi-
cance was calculated by using the Student’s t-test.
Differentiation assays
To induce U937 monocytic differentiation, cells were treated
with 0.5 nM PMA (Sigma, St Louis, MO), for 48 hours. Dif-
ferentiation was assessed by cytofluorimetric analysis of the
CD11b myeloid marker. Granulocytic differentiation of 32D
cells was induced by replacing IL-3 with human G-CSF
(Amgen, Thousand Oaks, CA) at the indicated concentra-
tions. Cells were counted daily using a Beckman Coulter cell
counter to obtain a growth curve and diluted daily to
0.2 × 106 cells/ml. Differentiation was either microscopically
evaluated on Giemsa-stained cytospin preparations, or
assessed by CD11b cytofluorimetric analysis. Treatments
with imatinib (Cayman Chemical, Ann Arbor, MI) were per-
formed at 1 μM concentration in the G-CSF containing
medium, based on [35]. Differences in proliferation or
CD11b levels between clones were analyzed by per-
forming ANOVA statistical analysis. For CD11b, ANOVA
analysis was performed between dose and clone condi-
tional on time, and time and clone conditional on dose.
Additional files
Additional file 1: Figure S1. Evidence of concomitant upregulation of
KIT and miR-17 in non-CBF-AML (A) Scheme showing the putative miRNA-
target sites in the RUNX1-3′UTR, as predicted by TargetScan analysis.
(B) Analysis of published miRNA data sets [24,25] from AML patientsamples showing that miR-17 is upregulated in non-CBF-AML relative
to CBF-AML (top); the upregulation is mostly observed in FAB M5 AML
(bottom). (C) Analysis of leukemic mononuclear cells isolated from the
bone marrow of non-CBF-AML patients showing concomitant upregulation
of KIT (measured by flow cytometry) and miR-17 (measured by qRT-PCR) in
three out of 10 cases. Figure S2. Additional miRNAs regulated by RUNX1
and deregulated by ectopic expression of CBF-AML fusion proteins or
miR-17. Stable ectopic expression of RUNX1-MTG8, CBFB-MYH11, or
miR-17 in U937 cells (a representative U937 clone is shown for each
construct) leads to downregulation of miR-193a, a RUNX1-regulated
miRNA targeting KIT (left), and miR-27a, a RUNX1-regulated miRNA
involved in myeloid differentiation (right). Figure S3. Additional miRNAs
regulated by RUNX1 showing upregulation in non-CBF-AML (A) In addition
to miR-17, Targetscan analysis identifies several other miRNAs targeting
RUNX1-3′UTR. (B) Analysis of published miRNA data sets [24,25] from AML
patient samples shows that a few of these miRNAs are upregulated in
non-CBF-AML and are associated with distinct AML FAB subtypes.
Additional file 2: Table S1. List of miRNAs predicted to target RUNX1-3′
UTR by Targetscan analysis.
Additional file 3: Table S2. List of miRNAs predicted to target KIT 3′UTR
by Targetscan analysis.
Additional file 4: Table S3. Statistical analysis of 32D growth curves
and CD11b expression.
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